Skip to main content

The Monthly Buprenorphine Shot Gives People Their Mornings Back. The System Still Rations It.

New Ontario overdose data and San Francisco's walk-in injections point the same direction. Prior authorization, REMS rules and old habits about daily dosing are still in the way.

ByThe Rize NewsroomNovember 15, 20269 min readOpioids

The sentence that explains this whole story came from a patient in a Swedish addiction clinic, interviewed sometime between May 2020 and March 2021, whose name the researchers never published. “When I wake up,” the person said, “I don’t have to think about having to take some medication sort of thing.” Another patient in the same study said it more simply: “I think I feel free in a different way.” A third talked about time, the hours that used to go to clinic lines and pharmacy counters: “I have much more time with my partner.” They were all getting a buprenorphine injection that lasts a week or a month instead of a film or tablet taken every single day.

If you have ever been on daily medication for opioid use disorder, you know what those people were describing. It is not the medicine. It is the negotiation, every morning, with the thing you are trying to get away from.

The monthly shot is the closest thing recovery medicine has to giving people their mornings back, and the American system still treats it like a luxury item.

This week brought two pieces of news that should push it out of that category. In Ontario, a clinician-researcher reported overdose deaths across tens of thousands of people that point toward the long-acting injection as the most protective form of opioid treatment. In San Francisco, the health department started offering the shot on demand at an urgent-care-style clinic. Neither is the final word. Both say the same thing: the form a medicine takes is part of the medicine. This piece is part of our ongoing treatment and recovery coverage.

The Ontario numbers are striking, and you should read them with one eye closed

On November 12, CTV News London reported on work led by Dr. Kenneth Lee, medical director of London’s Rapid Access Addiction Medicine (RAAM) clinic, the walk-in addiction clinic where Sublocade, the monthly buprenorphine shot, was first given in Canada in 2019. Lee’s team looked at 45,243 people in Ontario who had at least one opioid overdose between 2022 and 2024. Among them were 4,109 non-fatal and 770 fatal overdose cases. When CTV listed the deaths by treatment, 58 were people on methadone, 37 on Suboxone (daily buprenorphine), 18 on Kadian (slow-release oral morphine), and fewer than five on Sublocade. “What it means is, if people are on methadone or Suboxone, you can still overdose,” Lee told CTV. “But the beauty of this is that we have the secondary benefit of overdose protection.”

Now the eye you keep closed. Those are raw counts, and far fewer Ontarians are on the monthly shot than on methadone, so “fewer than five deaths” does not by itself mean “five times safer.” The version of the study we could verify is an April 2026 poster from the American Society of Addiction Medicine meeting, a nested case-control design (it compares people who overdosed with similar people who did not, and asks what treatment each was on). The poster is hosted on the website of Indivior, the company that makes Sublocade. CTV says the work appears in Frontiers in Public Health; we could not find that paper, so treat the effect size as unpublished until it is. Lee was careful in his own framing too: the protection he describes applies to fentanyl, not to everything else in the supply.

What keeps the Ontario signal from being a single press cycle is that it lines up with the biology. In a 2025 review in Substance Abuse and Rehabilitation, Lee and five co-authors explain why. Buprenorphine sits on the same brain receptors fentanyl wants. A daily film gives you a peak and a trough every 24 hours. An injection keeps the level steady, and steadier levels were linked in a small crossover study to less of fentanyl’s breath-stopping effect. In plain terms: the shot keeps the door mostly closed all the time, instead of leaving it cracked open every evening before the next dose. The review also notes that in clinical practice the extended-release form has been associated with fewer non-fatal overdoses than daily buprenorphine or methadone, and that people who inject may need higher blood levels (about 5–6 ng/mL versus 2–3) to stop using. That is calibrated evidence: consistent, plausible, mostly observational, not yet a randomized head-to-head trial on death.

In a 2025 review in Substance Abuse and Rehabilitation, Lee and five co-authors explain why.

Freedom from the daily dose is a clinical outcome, not a convenience

The overdose numbers will get the headlines. The Swedish interviews explain why people stay. Björn Johnson, Olivia Liahaugen Flensburg and Andrea Johansson Capusan interviewed 32 adults across seven Swedish clinics: 14 on the injection, 11 who had stopped it, seven who had said no. The people who stayed kept describing something psychologists would call a drop in cognitive load, the background mental effort a task takes even when you are not doing it. Daily dosing means the drug is on your calendar, in your pocket, on your mind. One patient said simply, “It was just this, that I don’t have to come here all the time.” Several described “feeling normal” for the first time in years.

That matters because the hardest part of opioid treatment in the United States is not starting. It is staying. People drop off daily buprenorphine for reasons that have nothing to do with wanting to use: a lost film, a pharmacy that will not stock it, a refill that falls on a weekend, a bad week where the daily reminder of what you are recovering from becomes too much. An injection removes most of those failure points at once. When the FDA updated Sublocade’s label in February 2025, it allowed clinicians to start the shot after one test dose of buprenorphine and an hour of observation instead of a week of daily films first. In the trial behind that change, among people who tested positive for fentanyl, 62.8% of those started the fast way came back for a second injection, versus 47.9% on the old schedule. Fifteen points of retention, from cutting out one week of hoops.

The same Swedish study is honest about the downside, and you should be too. Some people who stopped the injection described lumps at the injection site and withdrawal before the next dose: “Then the whole weekend was crap.” Some who declined it said the daily routine was what held them together. “It sits quite deep, that you have to take your medication every day,” one said. That is not irrational. For some people the morning dose is a ritual of recommitment. The point is not that everyone should switch. The point is that the choice should be real, and right now, for most Americans, it is not.

We built daily dosing as a leash, and we are still unbuckling it

To understand why a shot that frees people from daily dosing feels radical, you have to remember why daily dosing exists. When the federal government wrote its first methadone rules in the early 1970s, it designed treatment around suspicion: take your dose in front of us, every day, and earn take-homes slowly by proving yourself. Patients called it “liquid handcuffs.” For nearly fifty years the rules barely moved. Then COVID-19 closed clinic lobbies and the government loosened take-home limits as an emergency measure. The predicted wave of diversion and death did not arrive, and in February 2024 SAMHSA made those flexibilities permanent in a final rule. It took a pandemic to prove that trusting patients was safe. We have covered the rural version of this fight, where people still drive hours for a daily methadone dose. The monthly shot is the next chapter of the same argument: the medicine works better when the system stops making people prove themselves every morning.

Which brings us to San Francisco. The city now offers the injection on demand at the Maria X Martinez Health Resource Center in SoMa, the San Francisco Chronicle reported this week, through a program the health department calls Direct-to-Inject. The city’s clinical guideline walks a clinician from assessing withdrawal straight to a weekly Brixadi injection, with sublingual buprenorphine as backup for cravings in the first days. You walk in using fentanyl, you can walk out with a week of steady medication in your body. That is what low-barrier looks like when it is designed around the person instead of the paperwork, and it rhymes with the evidence from mobile treatment units in HPTN 094: go to people, start them fast, keep them.

You walk in using fentanyl, you can walk out with a week of steady medication in your body.

What stands between you and the shot

Here is where we have to name the gates, because a federal approval is not the same thing as a shot in your arm. Both long-acting products, Sublocade and Brixadi, which the FDA approved in May 2023 in weekly and monthly doses, are sold under a REMS, a federal safety program that means a health care provider must give the injection in a certified health care setting. You cannot pick it up at the pharmacy and take it home. That alone excludes a lot of small practices that prescribe daily buprenorphine.

Then come the payers. In Arizona, the medication is on the books: Arizona Complete Health’s AHCCCS behavioral health drug list lists both Sublocade and Brixadi as preferred, with prior authorization required. Mercy Care’s request form asks whether the member is receiving psychosocial interventions and whether the prescriber checked the state prescription-monitoring database before each monthly injection. Each of those boxes is defensible on its own. Together they rebuild, on paper, the same daily-proof logic the shot was supposed to escape. And the stakes of friction are enormous: a review published this week in Frontiers in Public Health found that in 2022, only 25.1% of American adults who needed opioid use disorder treatment received any medication at all.

For providers, the move this week is concrete. At the next visit, ask every patient on daily buprenorphine one question: “Would a shot that lasts a week or a month make your life easier?” Then do the unglamorous work: confirm your site is REMS-certified or partner with one that is, keep a pre-filled prior-authorization template for each AHCCCS plan you bill, and if you run an emergency department or urgent care, read San Francisco’s Direct-to-Inject protocol with your team. If you are the person in treatment, you are allowed to ask for this by name, and you are allowed to say no to it, too. And whatever form your medication takes, naloxone is still yours, still sold over the counter, and still worth keeping in the room. Our opioids coverage will keep tracking which plans make this easy and which do not.

The patient in Sweden did not describe a cure. They described waking up and not having to think about it. That is a small sentence about a large thing: a day that starts with your life instead of your disease. We have the medicine that makes those mornings possible. What we do not yet have is a system willing to stop asking people to earn them.

Filed Under

treatmentpsychologyharm-reductionMAT — BuprenorphineFentanylOverdoseThe Treatment GapPeer-Reviewed ResearchFDAAHCCCSArizona

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section